By Scott Graham | July 27, 2017
An Irell team led by partners David Gindler and Jason Sheasby represented New York-based Regeneron Pharmaceuticals during district court proceedings that ended in a highly critical ruling and invalidation of a Regeneron patent.
By therecorder | The Recorder | July 10, 2017
9th Cir.; 15-16380 The court of appeals reversed a judgment. The court held that relators adequately alleged a drug manufacturer’s violations of…
By P.J. D'Annunzio | July 7, 2017
A federal appeals court has reinstated a False Claims Act case alleging Gilead Sciences Inc. received billions in government reimbursements for HIV drugs that weren't qualified under the Food and Drug Administration.
By therecorder | The Recorder | July 3, 2017
C.A. 2nd; B238339 The Second Appellate District reversed a judgment and remanded. The court held that the jury’s finding of liability on a claim…
By Scott Graham | June 30, 2017
In the just-ended term, the U.S. Supreme Court reversed the Federal Circuit six times, wiping away patent law precedents that stood for decades. Would more face time heal the schism?
By therecorder | The Recorder | June 27, 2017
9th Cir.; 14-35402 The court of appeals reversed a judgment. The court held that intervenors needed to establish Article III standing in order to assert…
By Amanda Bronstad | June 20, 2017
Monday's landmark decision by the U.S. Supreme Court in "Bristol-Myers Squibb v. Superior Court of California" has already had a massive impact. In mere hours, a judge in Missouri granted a motion for mistrial in a pivotal trial over Johnson & Johnson's baby powder due to the court's decision. Even plaintiffs lawyers concede that "Bristol-Myers" took a hatchet to a lucrative growth area in mass torts: Lawsuits brought on behalf of dozens of individuals in venues considered more favorable to plaintiffs.
By therecorder | The Recorder | June 19, 2017
U.S. Sup. Ct.; 16–466 A group of plaintiffs, most of whom are not California residents, sued Bristol-Myers Squibb Company (BMS) in California state…
By Tony Mauro | June 19, 2017
In a win for the corporate defense bar, the U.S. Supreme Court on Monday tightened jurisdictional rules that determine where companies can be sued.
By Amanda Bronstad | June 15, 2017
Eli Lilly & Co. plans to move this month to dismiss a long-standing appeal in a case brought on behalf of a proposed class of consumers who used Cymbalta, an antidepressant prescription drug, according to a status report filed this week. The reason: Monday's decision by the U.S. Supreme Court in "Microsoft v. Baker," which blocked a controversial procedural tool that allowed plaintiffs to appeal class certification orders by dismissing their own case.
Presented by BigVoodoo
The National Law Journal honors attorneys & judges who've made a remarkable difference in the legal profession in the D.C. area.
New Jersey Law Journal honors lawyers leaving a mark on the legal community in New Jersey with their dedication to the profession.
This event shines a spotlight on the individuals, teams, projects and organizations that are changing the financial industry.
With bold growth in recent years, Fox Rothschild brings together 1,000 attorneys coast to coast. We offer the reach and resources of a natio...
About Us:Monjur.com is a leading provider of contracts-as-a-service for managed service providers, offering tailored solutions to streamline...
Dynamic Boutique law firm with offices in NYC, Westchester County and Dutchess County, is seeking a mid level litigation associate to work ...